OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Vokes on Investigative Biomarkers of Response to Checkpoint Inhibitors in Cancer

September 25th 2020

Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.

Dr. Azad on Unmet Needs in Metastatic Hormone-Sensitive Prostate Cancer

September 25th 2020

Arun Azad, PhD, discusses unmet needs for men with metastatic hormone-sensitive prostate cancer.

Dr. Nixon on the Role of MSI in Cancer

September 24th 2020

Andrew B. Nixon, PhD, MBA, discusses the role of microsatellite instability in cancer.

Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

September 24th 2020

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBC

September 24th 2020

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

Dr. Ma on the Utility of BTK Inhibitors in Relapsed/Refractory CLL

September 24th 2020

Shuo Ma, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory chronic lymphocytic leukemia.

Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL

September 24th 2020

Erlene Seymour, MD, discusses the progression-free survival benefit with acalabrutinib with or without obinutuzumab in chronic lymphocytic leukemia.

Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma

September 24th 2020

Mattia Garutti, MD, discusses the potential shift to neoadjuvant therapy in melanoma.

Dr. Rampal on the Evolving Understanding of Genomic Alterations in MPNs

September 24th 2020

Raajit K. Rampal, MD, PhD, discusses the evolving understanding of genetic alterations in myeloproliferative neoplasms.

Dr. Hussain on the Clinical Impact of the PROfound Trial in mCRPC

September 24th 2020

Maha Hussain, MD, FACP, FASCO, discusses the clinical impact of the phase 3 PROfound trial in metastatic castration-resistant prostate cancer.

Dr. Leslie on Sequencing Zanubrutinib in MCL

September 23rd 2020

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses sequencing strategies with zanubrutinib in mantle cell lymphoma.

Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer

September 23rd 2020

Erika P. Hamilton, MD, discusses the final overall survival results from the randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr. Mesa on Emerging Therapies in Myelofibrosis

September 23rd 2020

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Dr. Maddocks on Ongoing Sequencing Challenges in DLBCL

September 23rd 2020

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.

Dr. Burke on the Potential of Time-Limited BTK Inhibitor Therapy in B-Cell Malignancies

September 23rd 2020

John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.

Dr. Hill on the Impact of Recent Approvals in Relapsed/Refractory DLBCL

September 23rd 2020

Brian T. Hill, MD, PhD, discusses the impact of recent regulatory approvals in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Nguyen on the Optimal Duration of ADT in High-Risk Prostate Cancer

September 23rd 2020

Paul L. Nguyen, MD, discusses the optimal duration of androgen deprivation therapy in patients with high-risk prostate cancer.

Dr. Shore on the Objective of the HERO Trial in Advanced Prostate Cancer

September 23rd 2020

Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.

Dr. Choudhury on Treatment Goals in Nonmetastatic CRPC

September 23rd 2020

Atish D. Choudhury, MD, PhD, discusses the goal of treating patients with nonmetastatic castration-resistant prostate cancer.

Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma

September 22nd 2020

Alexander N. Shoushtari, MD, discusses the design of the phase 3 CheckMate-067 trial in advanced melanoma.